Jeremy S. Abramson

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon et al. · The Lancet · 2020 · 2.2K citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +5

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema et al. · New England Journal of Medicine · 2018 · 927 citations · Full text

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar, Scott R. Solomon, Jon Arnason et al. · The Lancet · 2022 · 704 citations

Second-line Treatment, Salvage Chemotherapy, Interim Analysis +9

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Adam M. Petrich, Mitul Gandhi, Borko Jovanovic et al. · Blood · 2014 · 461 citations

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

Nancy L. Bartlett, Wyndham H. Wilson, Sin‐Ho Jung et al. · Journal of Clinical Oncology · 2019 · 395 citations